

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for treating retinal and/or optic nerve head damage which comprises administering a pharmaceutically effective amount of a compound selected from the group consisting of Activity Dependent Neurotrophic Factor-9 (ADNF-9), and ADNF-14, ~~an ADNF peptidomimetic, an ADNF small molecule analogue, an agent that upregulates endogenous ADNF, and an expression vector that induces ADNF expression.~~

Claim 2 (previously presented) The method of claim 1, wherein the compound is ADNF-9.

Claim 3 (previously presented) The method of claim 1, wherein the compound is ADNF-14.

Claim 4 (currently amended) The method of claim 1, wherein the compound is administered by topical administration, ocular injection, implantation of a slow release device, or bolus, ~~or encapsulated cells which secretes the compound.~~

Claim 5 (previously presented) The method of claim 4, wherein the compound is administered by ocular injection.

Claim 6 (previously presented) The method of claim 5, wherein the compound is administered by intraocular injection.

Claim 7 (previously presented) The method of claim 5, wherein the compound is administered by periocular injection.

Claim 8 (currently amended) A method for decreasing retinal ganglion cell death, said method comprising administering a pharmaceutically effective amount of a compound selected from the group consisting of ADNF-9, and ADNF-14, ~~an ADNF peptidomimetic, an ADNF small molecule analogue, an agent that upregulates endogenous ADNF, and an expression vector that induces ADNF expression.~~

Claim 9 (previously presented) The method of claim 8, wherein the compound is ADNF-9.

Claim 10 (previously presented) The method of claim 8, wherein the compound is ADNF-14.

Claim 11 (currently amended) The method of claim 8, wherein the compound is administered by topical administration, ocular injection, implantation of a slow release device, or bolus, ~~or encapsulated cells which secretes the compound.~~

Serial No.: 09/920,931 (Conf #8818)

Filed: 2 August 2001

Page 3

Claim 12 (previously presented) The method of claim 11, wherein the compound is administered by ocular injection.

Claim 13 (previously presented) The method of claim 12, wherein the compound is administered by intraocular injection.

Claim 14 (previously presented) The method of claim 12, wherein the compound is administered by periocular injection.